MedWatch

Sunstone-company issues shares for three-digit million sum

Swedish biotech firm Cantargia makes a directed share issue of SEK 106 million to finance further development of the company's lead candidate, an antibody treatment against two types of cancer. Sunstone Capital forebodes its exit from the company but takes its time.

Pursuant to the general meeting’s authorization, the board of Swedish biotech company Cantargia has resolved a directed share issue of approximately SEK 106 million (USD 11.44 million).

Cantargia develops cancer therapies and fresh funds are to finance two new clinical programs for the company's main candidate, writes the company in a press release.

Læs hele artiklen

Få 14 dages fri adgang.
Det kræver intet kreditkort.

  • Adgang til alle låste artikler
  • Modtag vores daglige nyhedsbreve
  • Fuld adgang til vores app
Der skete en fejl. Prøv venligst igen senere

Få fuld adgang til dig og dine kollegaer.

Start et gratis virksomhedsprøveabonnement

Mere fra MedWatch

Relaterede

Seneste nyt

Ledige job

Se flere jobs

Se flere jobs

Latest news

Seneste nyt fra Watch Medier